Alopecia associated with ritonavir-boosted atazanavir therapy

被引：3
|
作者：
Torres, Harrys A.
Barnetth, Ben J.
Arduino, Roberto C.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis Infec Control & Employee Hlth, Houston, TX 77030 USA
[2] Univ Texas, Hlth Sci Ctr, Houston Med Sch, Dept Internal Med,Div Infect Dis, Houston, TX USA
来源：
AIDS | 2007年 / 21卷 / 10期
关键词：
D O I：
10.1097/QAD.0b013e3281532b42
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1391 / 1392
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients
    Mallolas, J.
    Sarasa, M.
    Nomdedeu, M.
    Soriano, A.
    Lopez-Pua, Y.
    Blanco, J. L.
    Martinez, E.
    Gatell, J. M.
    HIV MEDICINE, 2007, 8 (02) : 131 - 134
  • [22] Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
    Dickinson, Laura
    Boffito, Marta
    Back, David
    Waters, Laura
    Else, Laura
    Davies, Geraint
    Khoo, Saye
    Pozniak, Anton
    Aarons, Leon
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) : 1233 - 1243
  • [23] Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir
    Guiard-Schmid, JB
    Poirier, JM
    Bonnard, P
    Meynard, JL
    Slama, L
    Lukiana, T
    Jaillon, P
    Pialoux, G
    AIDS, 2005, 19 (16) : 1937 - 1938
  • [24] Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir
    Meynard, JL
    Poirier, JM
    Bonnard, P
    Meynard, JL
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (03) : 393 - 394
  • [25] Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257
    Ofotokun, Ighovwerha
    Na, Lumine H.
    Landovitz, Raphael J.
    Ribaudo, Heather J.
    McComsey, Grace A.
    Godfrey, Catherine
    Aweeka, Francesca
    Cohn, Susan E.
    Sagar, Manish
    Kuritzkes, Daniel R.
    Brown, Todd T.
    Patterson, Kristine B.
    Para, Michael F.
    Leavitt, Randi Y.
    Villasis-Keever, Angelina
    Baugh, Bryan P.
    Lennox, Jeffrey L.
    Currier, Judith S.
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (12) : 1842 - 1851
  • [26] Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
    Punyawudho, Baralee
    Thammajaruk, Narukjaporn
    Ruxrungtham, Kiat
    Avihingsanon, Anchalee
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 49 (03) : 327 - 332
  • [27] Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
    Maiara Camotti Montanha
    Francesc Fabrega
    Alice Howarth
    Nicolas Cottura
    Hannah Kinvig
    Fazila Bunglawala
    Andrew Lloyd
    Paolo Denti
    Catriona Waitt
    Marco Siccardi
    Clinical Pharmacokinetics, 2022, 61 : 375 - 386
  • [28] Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients
    Dailly, Eric
    Tribut, Olivier
    Tattevin, Pierre
    Arvieux, Cedric
    Perre, Philippe
    Raffi, Francois
    Jolliet, Pascale
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (07) : 523 - 526
  • [29] Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole
    Chan-Tack, KM
    Edozien, A
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (09) : 1344 - 1344
  • [30] Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients
    Eric Dailly
    Olivier Tribut
    Pierre Tattevin
    Cédric Arvieux
    Philippe Perré
    François Raffi
    Pascale Jolliet
    European Journal of Clinical Pharmacology, 2006, 62 : 523 - 526
12345